Asprin Dosing Estimator in Healthy Adults

Sponsor
University of Utah (Other)
Overall Status
Completed
CT.gov ID
NCT04040465
Collaborator
University of Colorado, Denver (Other)
57
Enrollment
1
Location
9
Arms
8.4
Actual Duration (Months)
6.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Understanding sources of variability in human drug dosing is important to the beneficial and safe use of any drug. Understanding and applying the science of individualizing a drug dose to a patient is called precision medicine.

Aspirin is one of the oldest most utilized medications for its ability to lower fever, relieve pain, and to reduce the stickiness of platelets (tiny blood cells that help your body form clots to stop bleeding. Aspirin dosing is currently the same for all patients and is not individualized. In the last century, aspirin has shown benefit in reducing cancer, stroke, and preventing cardiovascular events after one has already had a heart attack or stroke. Previous human studies have not found consistent positive effects of aspirin when dosed by body weight. Therefore, how should aspirin be dosed in 2019? Aspirin resistance is the failure of aspirin to reduce platelet stickiness and thin the blood and most importantly, is associated with higher risk of heart attacks and strokes. Aspirin resistance may occur due to not taking aspirin on a regular basis, differences in how platelets behave in some persons, use of over the counter pain medicines like Motrin®, reduced amount of drug in the body, and/or a lack of being able to predict a dose for a certain individual.

To find out the best way to dose aspirin, the investigators propose to study healthy volunteers (persons without any known disease) with different ages and body sizes to see if aspirin blood levels are tied to platelet stickiness. This information will be used to mathematically build a computer-based picture of aspirin dosing that will help physicians pick the best dose of aspirin for each patient. The investigators will then extend studies for the aspirin dose estimator to be used in other countries in people with heart problems and stroke, recording future events in a randomized (i.e., coin toss) manner, to determine if the ability of the aspirin dose estimator to prevent future heart attacks and stroke compared to people receiving aspirin doses that were chosen without the estimator.

Condition or DiseaseIntervention/TreatmentPhase
Early Phase 1

Detailed Description

AIM 1: Determine urine TXB2, platelet aggregation function testing (VerifyNow® ASA Test), salicylate level, CBC with differential, and hs-CRP, in 18 healthy volunteers across BMI classes of 22-25 (Normal Weight), >25-30 (Overweight), and > 30 kg/m2 (Obese).Total enrolled cohort: 60 patients and planned treatment cohort: 54 completed patients (anticipated dropout rate of 10% = 6 patients). The investigators have powered this sample size based on estimates of effect sizes from published studies examining platelet activation in patients across a range of BMIs and assuming an alpha = 0.05, with 80% power. In addition, height and weight as predictors will be evaluated independently of BMI. BMI patient groups (22-25, >25-30, and > 30 kg/m2) will be randomized to low-dose ASA (81mg standard-release), moderate dose ASA (325mg) or high dose ASA (500mg) (6 patients/each dose).

All patients will have a CBC with differential (to measure blood cell counts including platelets) and hs-CRP at baseline, serial urine TXB2 (-1, and 2 and 5 hours post ASA dose), platelet aggregation function testing using VerifyNow® ASA Test 15 min post ASA dose, serial salicylate levels (0, 15", 2 hours post-ASA dose) and again 10-14 days after chronic dosing (urine TXB2 2 hours post ASA dose and platelet aggregation function testing using VerifyNow® Test 15 min post ASA dose only).

AIM 2: Model associations between construct variables (BMI and aspirin dose) with predictive variables as collected in AIM 1. Multiple and Linear Regression with backward selection will be used. In addition, a Structured Equation Model will be applied to the data. Statistical assessment of model fit will be conducted for all models.

AIM 3: Build an Aspirin Dose Estimator to predict aspirin dosing. Model associations from AIM 2 will create demand estimates that will feed into a user-friendly aspirin dosage estimator. The simulator will comprise: 1) Entry: An entry screen. In this screen the user will enter the features of patient clinical information attributes. The user then clicks a 'run' button. 2) Demand Output: The simulator will then create an output screen that will show graphically aspirin dosing options.

Study Design

Study Type:
Interventional
Actual Enrollment :
57 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
We will place patients into 3 different groups based on BMI, and within those groups patients will be randomly assigned to an aspirin dose (81mg, 325mg, or 500mg)We will place patients into 3 different groups based on BMI, and within those groups patients will be randomly assigned to an aspirin dose (81mg, 325mg, or 500mg)
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Asprin Dosing Estimator in Healthy Adults
Actual Study Start Date :
Feb 15, 2021
Actual Primary Completion Date :
Oct 30, 2021
Actual Study Completion Date :
Oct 30, 2021

Arms and Interventions

ArmIntervention/Treatment
Active Comparator: Normal Weight/Low Dose Aspirin

BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks

Drug: Aspirin
Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Active Comparator: Normal Weight/Normal Dose Aspirin

BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks

Drug: Aspirin
Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Active Comparator: Normal Weight/High Dose Aspirin

BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks

Drug: Aspirin
Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Active Comparator: Overweight/Low Dose Aspirin

BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks

Drug: Aspirin
Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Active Comparator: Overweight/Normal Dose Aspirin

BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks

Drug: Aspirin
Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Active Comparator: Overweight/High Dose Aspirin

BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks

Drug: Aspirin
Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Active Comparator: Obese/Low Dose Aspirin

BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks

Drug: Aspirin
Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Active Comparator: Obese/Normal Dose Aspirin

BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks

Drug: Aspirin
Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Active Comparator: Obese/High Dose Aspirin

BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks

Drug: Aspirin
Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Outcome Measures

Primary Outcome Measures

  1. Height [2 weeks per participant]

    Used to measure BMI

  2. Weight [2 weeks per participant]

    Used to measure BMI

  3. Urine TBX2 Collection (Thromboxane levels) [2 weeks per participant]

    Thromboxane levels measured for indicator of platelet aggregation function

  4. Salicylate Levels [2 weeks per participant]

    Used to measure amount of systemic aspirin to compare with TBX2 and BMI categories

  5. Aspirin Reaction Units (ARU) [2 weeks per participant]

    Number given from Verifynow device that will be used to determine platelet aggregation function by arachidonic acid induced aggregation

Secondary Outcome Measures

  1. Complete Blood Count (CBC) [2 weeks per participant]

    Safety measure labs taken on 2 visits

  2. High-sensitivity C-reactive protein (hs-CRP) [2 weeks per participant]

    Measured as an inflammatory marker and indicator of cardiac risk and risk of stroke

  3. Blood Pressure (mmHg) [2 weeks per participant]

    Safety measure taken on 2 visits

  4. Heart Rate (BPM) [2 weeks per participant]

    Safety measure taken on 2 visits

  5. Respiratory Rate (breaths per minute) [2 weeks per participant]

    Safety measure taken on 2 visits

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Ages 18-55 years old (male or female)

  • Healthy Volunteers (medication free without acute or chronic significant health problems or pathologies)

Exclusion Criteria:
  • History of asthma

  • History of chronic bronchitis

  • History of emphysema

  • History of renal impairment (eGFR < 30 ml/min)

  • History of hypertension (reviewed by study staff)

  • History of hyperlipidemia

  • History of diabetes

  • History of smoking (within last month)

  • Current depression or anxiety requiring medication therapy

  • Inability to finish the study for any reason

  • Any current pathological condition outside of normal range

  • Thrombocytopenia (platelet count < 150 K/µL)

  • Other known platelet disorders (eg. von Willebrand disease, Glanzmann thrombasthenia, Bernard-Soulier Syndrome)

  • Current use of dipyradamole, PGY 12 inhibitors, NSAIDs

  • Or as otherwise determined by the investigative team

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1University of UtahSalt Lake CityUtahUnited States84112

Sponsors and Collaborators

  • University of Utah
  • University of Colorado, Denver

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
mark munger, Principal Investigator, University of Utah
ClinicalTrials.gov Identifier:
NCT04040465
Other Study ID Numbers:
  • IRB_00117303
First Posted:
Jul 31, 2019
Last Update Posted:
Mar 11, 2022
Last Verified:
Oct 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 11, 2022